Evaluating the Effectiveness of a Weight Loss Program for Overweight and Obese People With Schizophrenia

2008 ◽  
Author(s):  
Rohan Ganguli
Nutrients ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1960
Author(s):  
Marlhyn Valero-Pérez ◽  
Laura M. Bermejo ◽  
Bricia López-Plaza ◽  
Meritxell Aguiló García ◽  
Samara Palma-Milla ◽  
...  

Obesity is a global public health problem. Objective: To evaluate the effect of the regular consumption of the product Lipigo® on body weight and rebound effect on overweight/obese subjects undergoing a comprehensive weight loss program. Methods: A randomized, parallel, double-blind, placebo-controlled clinical trial was conducted with male and female subjects presenting a BMI 25–39.9 kg/m2. All subjects underwent a comprehensive weight loss program (WLP) for 12 weeks, which included an individualized hypocaloric diet, physical activity recommendations, nutritional education seminars, and three times a day consumption of the product Lipigo® or Placebo. After-WLP, subjects continued the treatment for 9 months to assess rebound effect. Body weight (BW), BMI, and body composition were measured at the beginning and the end of the WLP, and in the follow-up. Results: A total of 120 subjects (85% women) 49.0 ± 9.5 years old and with a BW of 81.57 ± 13.26 kg (BMI 31.19 ± 3.44 kg/m2) were randomized and 73 subjects finished the study. At the end of the WLP, there was a tendency toward reduced BW (p = 0.093), BMI (p = 0.063), and WC (p = 0.059) in the treated group. However, subjects with obesity type 1 (OB1) from the treated group significantly reduced body weight (−5.27 ± 2.75 vs. −3.08 ± 1.73 kg; p = 0.017) and BMI (−1.99 ± 1.08 vs. −1.09 ± 0.55 kg/m2; p = 0.01) compared with placebo. They also presented a minor rebound effect after 9 months with product consumption (−4.19 ± 3.61 vs. −1.44 ± 2.51 kg; p = 0.026), minor BMI (−1.61 ± 1.43 vs. −0.52 ± 0.96 kg/m2; p = 0.025) and tended to have less fat-mass (−3.44 ± 2.46 vs. −1.44 ± 3.29 kg; p = 0.080) compared with placebo. Conclusions: The regular consumption of the product Lipigo® promotes the reduction of body weight and reduces the rebound effect of obese people after 52 weeks (12 months), mainly in obesity type 1, who undergo a comprehensive weight loss program.


Author(s):  
Chia-Po Fu ◽  
Wayne H.-H. Sheu ◽  
I.-Te Lee ◽  
Wen-Jane Lee ◽  
Jun-Sing Wang ◽  
...  

AbstractMonocyte chemoattractant protein-1 (MCP-1) is involved in obesity-related renal injury. The aim of the present study was to examine the effects of weight loss on changes in MCP-1 and markers of renal injury, specifically serum cystatin C (S-CysC) and urinary N-acetyl glucosaminidase (UNAG), in obese people.In this prospective study, 40 obese men with metabolic syndrome (MetS) participated in a 3-month dietary and exercise intervention. Twenty-eight subjects completed the study with a ≥5% weight loss. Circulating MCP-1, S-CysC and UNAG to creatinine ratio (UNCR) were determined before and after the weight loss program.Obesity-associated components of MetS demonstrated significant improvements after the weight loss program. In addition, at baseline, circulating MCP-1 concentrations were positively correlated with UNCR and S-CysC levels. After weight loss, blood MCP-1 and UNCR levels were significantly decreased, but S-CysC was not affected. Using multiple linear regression analysis, there was a significant relationship between changes in UNCR and MCP-1 after adjusting for other potential confounding factors.Weight loss may improve renal tubular injury by ameliorating obesity-related inflammation in obese men with MetS.


2008 ◽  
Vol 27 (1, Suppl) ◽  
pp. S91-S98 ◽  
Author(s):  
Sherry L. Pagoto ◽  
Lyle Kantor ◽  
Jamie S. Bodenlos ◽  
Mitchell Gitkind ◽  
Yunsheng Ma

2011 ◽  
Vol 41 (10) ◽  
pp. 34
Author(s):  
M. ALEXANDER OTTO

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 57-LB
Author(s):  
KARLA B. DETOYA ◽  
KATRINA HAN ◽  
BRENNAN R. REGISTER ◽  
DAVID A. ROMETO

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
I Gusti Bagus Astawa ◽  
I Ketut Agung Enriko

These days, the use of Internet technology can be found in almost every sector of human life. One of the advanced Internet technologies is Internet of Things (IoT), that is a technology where devices can communicate via Internet connectivity. It is used in many vital industries like automotive, electricity, home automation, and healthcare. This study aims to implement IoT technology for healthcare sector, i.e. in helping obesity people to pursue their weight-loss program (WLP). The result is a system which consists of a smart weight scale, a mobile application, and food menu recommendation database in order to help obesity people in their WLP program. A trial to some obesity patients is performed to collect data. Index Terms—Internet of things; overweight; weight loss program; food recommendation


Sign in / Sign up

Export Citation Format

Share Document